Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis

Kristie Rebecca Weir, Nagham J Ailabouni, Carl R Schneider, Sarah N Hilmer, Emily Reeve, Kristie Rebecca Weir, Nagham J Ailabouni, Carl R Schneider, Sarah N Hilmer, Emily Reeve

Abstract

Background: Harmful and/or unnecessary medication use in older adults is common. This indicates deprescribing (supervised withdrawal of inappropriate medicines) is not happening as often as it should. This study aimed to synthesize the results of the Patients' Attitudes Towards Deprescribing (PATD) questionnaire (and revised versions).

Methods: Databases were searched from January 2013 to March 2020. Google Scholar was used for citation searching of the development and validation manuscripts to identify original research using the validated PATD, revised PATD (older adult and caregiver versions), and the version for people with cognitive impairment (rPATDcog). Two authors extracted data independently. A meta-analysis of proportions (random-effects model) was conducted with subgroup meta-analyses for setting and population. The primary outcome was the question: "If my doctor said it was possible, I would be willing to stop one or more of my medicines." Secondary outcomes were associations between participant characteristics and primary outcome and other (r)PATD results.

Results: We included 46 articles describing 40 studies (n = 10,816 participants). The meta-analysis found the proportion of participants who agreed or strongly agreed with this statement was 84% (95% CI 81%-88%) and 80% (95% CI 74%-86%) in patients and caregivers, respectively, with significant heterogeneity (I2 = 95% and 77%).

Conclusion: Consumers reported willingness to have a medication deprescribed although results should be interpreted with caution due to heterogeneity. The findings from this study moves toward understanding attitudes toward deprescribing, which could increase the discussion and uptake of deprescribing recommendations in clinical practice.

Keywords: Caregivers; Inappropriate prescribing; Medications; Older adults; Polypharmacy.

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America.

Figures

Figure 1.
Figure 1.
Forest plots of proportion of participants who agreed or strongly agreed with the question “If my doctor said it was possible, I would be willing to stop one or more of my medicines”. (A) Forest plot patients. (B) Forest plot caregivers.

References

    1. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995. doi:10.1016/j.jclinepi.2012.02.018
    1. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing. Drugs Aging. 2012;29(6):437–452. doi:10.2165/11632610-000000000-00000
    1. Panel AGSBCUE, Fick DM, Semla TP, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4): 674–694.
    1. Steinman MA, Miao Y, Boscardin WJ, Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014;29(10):1379–1386. doi:10.1007/s11606-014-2924-8
    1. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86–88. doi:10.1038/clpt.2008.224
    1. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181–187. doi:10.1016/j.jamda.2019.10.022
    1. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017;57(6):729–738.e10. doi:10.1016/j.japh.2017.06.002
    1. Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schöttker B. The association of potentially inappropriate medication at older age with cardiovascular events and overall mortality: a systematic review and meta-analysis of cohort studies. J Am Med Dir Assoc. 2017;18(3):211–220. doi:10.1016/j.jamda.2016.11.025
    1. Hyttinen V, Jyrkkä J, Valtonen H. A systematic review of the impact of potentially inappropriate medication on health care utilization and costs among older adults. Med Care. 2016;54(10):950–964. doi:10.1097/MLR.0000000000000587
    1. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Med. 2015:E1–E8. doi:10.1001/jamainternmed.2015.0324
    1. Reeve E, Gnjidic D, Long J, Hilmer SJBjocp. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–1268. doi:10.1111/bcp.12732
    1. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623. doi:10.1111/bcp.12975
    1. Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303–319. doi:10.1007/s40266-018-0536-4
    1. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS One. 2016;11(4):e0151066. doi:10.1371/journal.pone.0151066
    1. Thompson W, Le JV, Haastrup P, Nielsen JB, Pedersen LB, Jarbøl DE. Exploring how GPs discuss statin deprescribing with older people: a qualitative study. BJGP Open. 2020;4(1). doi:10.3399/bjgpopen20X101022
    1. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. doi:10.1136/bmjopen-2014-006544
    1. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Development and validation of the Patients’ Attitudes Towards Deprescribing (PATD) questionnaire. Int J Clin Pharm. 2013;35(1):51–56. doi:10.1007/s11096-012-9704-5
    1. Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–928. doi:10.1007/s40266-016-0410-1
    1. Reeve E, Anthony AC, Kouladjian O’Donnell L, et al. Development and pilot testing of the revised Patients’ Attitudes Towards Deprescribing questionnaire for people with cognitive impairment. Australas J Ageing. 2018;37(4):E150–E154. doi:10.1111/ajag.12576
    1. Bennett C, Khangura S, Brehaut JC, et al. Reporting guidelines for survey research: an analysis of published guidance and reporting practices. PLoS Med. 2010;8(8):e1001069. doi:10.1371/journal.pmed.1001069
    1. Anderson K. Minimising potentially inappropriate polypharmacy in community living older people: a multi-phase, mixed methods study to develop and pilot a general practitioner-led deprescribing intervention in primary care. 2018.
    1. Anderson K, Freeman C, Foster M, Scott I. GP-led deprescribing in community-living older Australians: an exploratory controlled trial. J Am Geriatr Soc. 2020;68(2):403–410. doi:10.1111/jgs.16273
    1. Cross AJ, George J, Woodward MC, Le VJ, Elliott RA. Deprescribing potentially inappropriate medications in memory clinic patients (DePIMM): a feasibility study. Res Social Adm Pharm. 2020.
    1. Gillespie R, Mullan J, Harrison L. Attitudes towards deprescribing and the influence of health literacy among older Australians. Prim Health Care Res Dev. 2019;20:e78. doi:10.1017/S1463423618000919
    1. Gnjidic D, Ong HMM, Leung C, Jansen J, Reeve E. The impact of in hospital patient-education intervention on older people’s attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. Ther Adv Drug Saf. 2019;10:2042098618816562. doi:10.1177/2042098618816562
    1. Hendrix I, Page AT, Korhonen MJ, et al. Patterns of high-dose and long-term proton pump inhibitor use: a cross-sectional study in six south Australian residential aged care services. Drugs Real World Outcomes. 2019;6(3):105–113. doi:10.1007/s40801-019-0157-1
    1. Kalogianis MJ, Wimmer BC, Turner JP, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Social Adm Pharm. 2016;12(5):784–788. doi:10.1016/j.sapharm.2015.12.004
    1. Major GL, Mills A, Lowthian JA. Deprescribing attitudes of older adults receiving medication management support from home-based nurses. J Am Geriatr Soc. 2019;67(8):1756–1757. doi:10.1111/jgs.16015
    1. Qi K, Reeve E, Hilmer SN, Pearson SA, Matthews S, Gnjidic D. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949–957. doi:10.1007/s11096-015-0147-7
    1. Reeve E. Development and Feasibility of a Patient-Centred Deprescribing Process [PhD Thesis]. Adelaide, Australia: University of South Australia; 2014.
    1. Reeve E, Low LF, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc. 2019;67(6):1204–1210. doi:10.1111/jgs.15804
    1. Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S. People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc. 2013;61(9):1508–1514. doi:10.1111/jgs.12418
    1. Hao LJ, Omar MS, Tohit N. Polypharmacy and willingness to deprescribe among elderly with chronic diseases. Int J Gerontol. 2018;12(4):340–343.
    1. Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. A comment. Int J Clin Pharm. 2019;41(5):1131–1132. doi:10.1007/s11096-019-00891-7
    1. Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. Int J Clin Pharm. 2019;41(3):793–803. doi:10.1007/s11096-019-00829-z
    1. Ng KY, Lee SWH. Attitude of older patients with Parkinson’s disease towards deprescribing: a pilot study. J Parkinson’s Dis. 2019;9(1):101.
    1. Omar MS, Ariandi AH, Tohit NM. Practical problems of medication use in the elderly Malaysians and their beliefs and attitudes toward deprescribing of medications. J Res Pharm Pract. 2019;8(3):105–111. doi:10.4103/jrpp.JRPP_19_35
    1. Goulding H. Quality Improvement Project on Optimising Medications – Serious Mental Illness. Pittsburgh, PA: University of Pittsburgh; 2018.
    1. Ikeji C, Williams A, Hennawi G, Brandt NJ. Patient and provider perspectives on deprescribing proton pump inhibitors. J Gerontol Nurs. 2019;45(10):9–17. doi:10.3928/00989134-20190912-03
    1. Ikeji CA, Brandt N, Hennawi G, Williams A. Patient and prescriber perspectives on proton pump inhibitor (PPI) use and deprescribing in older adults. J Am Geriatr Soc. 2019;67(suppl 1):S287.
    1. Martinez AI, Spencer J, Moloney M, Badour C, Reeve E, Moga DC. Attitudes toward deprescribing in a middle-aged health disparities population. Res Social Adm Pharm. 2020;16(10):1502–1507. doi:10.1016/j.sapharm.2020.02.014
    1. Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673–1680. doi:10.1001/jamainternmed.2018.4720
    1. Sirois C, Ouellet N, Reeve E. Community-dwelling older people’s attitudes towards deprescribing in Canada. Res Social Adm Pharm. 2017;13(4):864–870. doi:10.1016/j.sapharm.2016.08.006
    1. Turner JP, Martin P, Zhang YZ, Tannenbaum C. Patients beliefs and attitudes towards deprescribing: can deprescribing success be predicted? Res Social Adm Pharm. 2020;16(4):599–604. doi:10.1016/j.sapharm.2019.07.007
    1. Whitty R, Porter S, Battu K, et al. A pilot study of a Medication Rationalization (MERA) intervention. CMAJ Open. 2018;6(1):E87–E94. doi:10.9778/cmajo.20170134
    1. Edelman M, Blanker M, Jellema P, Hak E, Denig P. Patient attitudes towards deprescribing of alpha-blockers and willingness to participate in a discontinuation trial. Neurourol Urodyn. 2017;36(suppl 3):S242–S244.
    1. Edelman M, Jellema P, Hak E, Denig P, Blanker MH. Patients’ attitudes towards deprescribing alpha-blockers and their willingness to participate in a discontinuation trial. Drugs Aging. 2019;36(12):1133–1139. doi:10.1007/s40266-019-00712-6
    1. Frankowski NEDM, Grootens KP, van der Stelt CA, Noort A, van Marum RJ. ‘You tell me, you are the doctor’; patients on long-term psychiatric residences about their medication. Tijdschr Psychiatr. 2019;61(8):527–535.
    1. Van Marum RJ, Van Marum S, Van Driesten S, Verdoorn S, Boxman A, Grossklaus A. Deprescribing for the elderly: comparing opinions of patients, pharmacists and doctors. Pharm Weekbl. 2016;151(43):28–33.
    1. Lundby C, Simonsen T, Ryg J, Sondergaard J, Pottegard A, Lauridsen HH. Translation, cultural adaptation, and psychometric properties of the Danish version of the revised patients’ attitudes towards deprescribing questionnaire. Pharmacoepidemiol Drug Saf. 2019;28(suppl 2):291–292.
    1. Schiøtz ML, Frølich A, Jensen AK, et al. Polypharmacy and medication deprescribing: a survey among multimorbid older adults in Denmark. Pharmacol Res Perspect. 2018;6(6).
    1. Kua CH, Reeve E, Ratnasingam V, Mak VSL, Lee SWH; Pharmaceutical Society of Singapore Deprescribing Workgroup . Patients’ and caregivers’ attitudes towards deprescribing in Singapore. J Gerontol A Biol Sci Med Sci. 2020;22:22.
    1. Ng WL, Tan MZW, Koh EYL, Tan NC. Deprescribing: What are the views and factors influencing this concept among patients with chronic diseases in a developed Asian community? Proc Singapore Healthcare. 2017;26(3):172–179.
    1. Nusair MB, Arabyat R, Al-Azzam S, El-Hajji FD, Nusir AT, Al-Batineh M. Translation and psychometric properties of the Arabic version of the revised Patients’ Attitudes Towards Deprescribing questionnaire. J Pharm Health Serv Res. 2020.
    1. Paque K, Elseviers M, Vander Stichele R, et al. Balancing medication use in nursing home residents with life-limiting disease. Eur J Clin Pharmacol. 2019;75(7):969–977. doi:10.1007/s00228-019-02649-6
    1. Tegegn HG, Tefera YG, Erku DA, et al. Older patients’ perception of deprescribing in resource-limited settings: a cross-sectional study in an Ethiopia university hospital. BMJ Open. 2018;8(4):e020590. doi:10.1136/bmjopen-2017-020590
    1. Saraswathy GR, Pratheeksha M, Maheswari E. Analysing the attitude of old age home residents on polypharmacy and deprescribing of medications in Mangalore, Karnataka. Value Health. 2018;21(suppl 3):S220.
    1. Galazzi A, Lusignani M, Chiarelli MT, et al. Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy. Int J Clin Pharm. 2016;38(2):454–461. doi:10.1007/s11096-016-0279-4
    1. Candela M. Ánalisis de la complejidad farmacoterapéutica y la necesidad potencial de desprescripción en pacientes con infección por el VIH. Proyecto Invest. 2019.
    1. Aoki T, Yamamoto Y, Ikenoue T, Fukuhara S. Factors associated with patient preferences towards deprescribing: a survey of adult patients on prescribed medications. Int J Clin Pharm. 2019;41(2):531–537. doi:10.1007/s11096-019-00797-4
    1. ul Haq N, Mohaib M, Nasim A, Razaque G, Riaz S. Chronic patients attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe in Quetta. Value Health. 2016;19(7):A823.
    1. Cardwell K, Smith SM, Clyne B, et al. ; General Practice Pharmacist (GPP) Study Group . Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. BMJ Open. 2020;10(6):e035087. doi:10.1136/bmjopen-2019-035087
    1. Scott S, Clark A, Farrow C, et al. Attitudinal predictors of older peoples’ and caregivers’ desire to deprescribe in hospital. BMC Geriatr. 2019;19(1):108. doi:10.1186/s12877-019-1127-x
    1. Linsky A, Simon SR, Stolzmann K, Lippin-Foster RA, Meterko M. Patient Perceptions of Deprescribing (PPoD): survey development and validation. J Gen Intern Med. 2016;31(2):S327.
    1. Linsky A, Simon SR, Stolzmann K, Meterko M. Patient attitudes and experiences that predict medication discontinuation in the Veterans Health Administration. J Am Pharm Assoc (2003). 2018;58(1):13–20. doi:10.1016/j.japh.2017.10.012
    1. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807. doi:10.1007/s40266-013-0106-8
    1. Weir K, Nickel B, Naganathan V, et al. Decision-making preferences and deprescribing: perspectives of older adults and companions about their medicines. J Gerontol B Psychol Sci Soc Sci. 2018;73(7):e98–e107. doi:10.1093/geronb/gbx138
    1. Weir KR, Naganathan V, Carter SM, et al. The role of older patients’ goals in GP decision-making about medicines: a qualitative study. BMC Fam Pract. 2021;22(1):13. doi:10.1186/s12875-020-01347-y
    1. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. Int J Clin Pract. 2016;70(3):261–276. doi:10.1111/ijcp.12780
    1. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. doi:10.1001/jamainternmed.2014.949
    1. Beer C, Loh PK, Peng YG, Potter K, Millar A. A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf. 2011;2(2):37–43. doi: 10.1177/2042098611400332
    1. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: a randomised controlled trial. PLoS One. 2016;11(3):e0149984. doi:10.1371/journal.pone.0149984
    1. Komagamine J, Sugawara K, Hagane K. Characteristics of elderly patients with polypharmacy who refuse to participate in an in-hospital deprescribing intervention: a retrospective cross-sectional study. BMC Geriatr. 2018;18(1):96. doi:10.1186/s12877-018-0788-1
    1. Ailabouni NJ, Reeve E. Can existing tools predict older adults’ willingness to deprescribe? Considerations for D-PRESCRIBE’s post-hoc secondary analysis. Res Social Adm Pharm. 2019;15(11):1379–1380. doi:10.1016/j.sapharm.2019.08.025
    1. Maher D, Ailabouni N, Mangoni AA, Wiese MD, Reeve E. Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opin Drug Metab Toxicol. 2021;17(1):41–52. doi:10.1080/17425255.2021.1839413
    1. Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893. doi:10.1136/bmj.i2893
    1. Linsky A, Gellad WF, Linder JA, Friedberg MW. Advancing the science of deprescribing: a novel comprehensive conceptual framework. J Am Geriatr Soc. 2019;67(10):2018–2022. doi:10.1111/jgs.16136
    1. Sawan M, O’Donnell LK, Reeve E, et al. The utility of a computerised clinical decision support system intervention in home medicines review: a mixed-methods process evaluation. Res Social Adm Pharm. 2021;17(4):715–722. doi:10.1016/j.sapharm.2020.06.010
    1. Kouladjian O’Donnell L, Gnjidic D, Sawan M, et al. Impact of the goal-directed medication review electronic decision support system on drug burden index: a cluster-randomised clinical trial in primary care. Br J Clin Pharmacol. 2021;87(3):1499–1511. doi:10.1111/bcp.14557
    1. Bayliss EA, Shetterly SM, Drace ML, et al. The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials. 2020;21(1):542. doi:10.1186/s13063-020-04482-0
    1. Green AR, Boyd CM, Gleason KS, et al. Designing a primary care–based deprescribing intervention for patients with dementia and multiple chronic conditions: a qualitative study. J Gen Intern Med. 2020:1–8.
    1. Thompson W, Reeve E, Moriarty F, et al. Deprescribing: future directions for research. Res Social Adm Pharm. 2019;15(6):801–805. doi:10.1016/j.sapharm.2018.08.013

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner